{"entity":{"id":"nct06387342","kind":"trial","name":"Namodenoson Treatment of Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Namodenoson 25mg in pancreatic ductal adenocarcinoma, run by Can-Fite BioPharma, now recruiting.","summary":"Namodenoson Treatment of Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT06387342 by Can-Fite BioPharma, with 20 participants planned, started 2024-11-10 and due to reach its primary completion in 2026-07-15. Interventions recorded: Namodenoson 25mg.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06387342","url":"https://clinicaltrials.gov/study/NCT06387342"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["can-fite"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06387342","phase":"2","setting":"CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma","sponsor":"Can-Fite BioPharma","enrolled":20,"outcomes":[]},"route":"/trials/nct06387342/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/"}]}}